OLIGONUCLEOTIDE THERAPEUTICS
2024
San Diego, February 28, 2024
Welcome to hubXchange’s San Diego Oligonucleotide Therapeutics 2024, bringing together executives from pharma and biotech to address and find solutions to the key issues faced in oligonucleotide therapeutics.
Discussion topics will cover New Modalities, Oligonucleotide Discovery, Manufacturing and Drug Delivery.
Take advantage of this unique highly interactive meeting format designed for maximum engagement, collaboration and networking with your peers.
Venue: Handlery Hotel San Diego, 950 Hotel Circle North, San Diego CA 92108
SNAPSHOTS OF DISCUSSION TOPICS
- Drugging the genome to address base casuality
- Enabling cell type specific expression from RNA vectors
- Challenges in the synthesis and development of long oligos for editing
- Best practice for the oligonucleotide therapeutics hit-to-lead process
- Effective strategy for screening oligonucleotides at early stage
- Digital process and product development for oligonucleotide therapeutics
- Regulatory CMC challenges
- Challenges in drug substance and drug product manufacturing
- New receptors for targeted delivery of oligonucleotides
- Revisiting peptide and lipid conjugation for oligonucleotide delivery
Full Xchange Agenda
Click on each track for detailed agenda
New Modalities
Overcoming challenges in the utilisiation of novel self-amplifying RNA (saRNA) vaccines for emerging and endemic infections
- saRNA in the size range 9-16 kb have been historically very difficult to manufacture
- saRNA has a significantly more challenging stability profile than conventional linear mRNA
- Public perception of saRNA will be challenging for prophylactic vaccines given the current resistance encounter for the COVID-19 mRNA vaccines
Dr. Andy Geall is the Chief Development Officer and cofounder of Replicate Bioscience, a San Diego (California) based Biotech. The company has developed a diverse proprietary repertoire of virally derived self-replicating RNA vectors, which are being used to tackle a range of disease indications in oncology, infectious disease, autoimmune and inflammatory disorders. Dr. Geall has over 20 years of professional experience in the development of drug delivery systems and is a pioneer in the fields of mRNA vaccines and nucleic acid delivery. He is an inventor on 41 patent families, with 505 applications and 203 issued patents in multiple jurisdictions.
Networking Lunch
Spotlight Presentation by PolyPeptide
What Are Your Expectations of a Drug Substance Oligonucleotide Contract Manufacturer?
Enhancing the effectiveness of oligonucleotide therapeutics through medicinal chemistry
- What key properties of oligonucleotide therapeutics do you feel are the most amenable to being impacted by medicinal chemistry?
- Traditionally, performing high-throughput medicinal chemistry on oligonucleotides has proven challenging, what approaches do you take to innovate in this area?
- What classes of modifications do you find most interesting (sugar, phosphate, nucleobase, etc.)?
Kyle Knouse received his B.S in Chemistry from Temple University in Philadelphia working on novel antibiotic compounds to overcome resistance mechanisms, he then moved to San Diego where he received his Ph.D. in Chemistry from the Scripps Research Institute working in the lab of Phil S. Baran on novel organophosphorus chemistry. In 2021 he co-founded Elsie Biotechnologies where he is currently the Director of Chemistry. At Elsie he works to enable performing high-throughput medicinal chemistry on oligonucleotide therapeutics and explores novel delivery strategies. He has published 18 peer reviewed articles and 6 patents.
